What is NDC 67877-606?

67877-606 is the product NDC for Buprenorphine And Naloxone, Buprenorphine hydrochloride 8 mg/1; Naloxone hydrochloride 2 mg/1 tablet, listed with the FDA by Ascend Laboratories, LLC. It has 3 package NDCs, shown above in 10- and 11-digit form.

What is the active ingredient?

Buprenorphine hydrochloride, Naloxone hydrochloride.

Ascend Laboratories, LLC, NDC labeler code 67877. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Buprenorphine And Naloxone?

50 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Buprenorphine And Naloxone NDC 67877-606

NDC codes

FDA NDC Directory

Product NDC (as listed)67877-606Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67877-0606Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
67877-606-30	6787706063067877060630	30 TABLET in 1 BOTTLE (67877-606-30)Marketed from Jul 3, 2026
67877-606-84	6787706068467877060684	3 BLISTER PACK in 1 CARTON (67877-606-84) / 10 TABLET in 1 BLISTER PACKMarketed from Jul 3, 2026
67877-606-90	6787706069067877060690	90 TABLET in 1 BOTTLE (67877-606-90)Marketed from Jul 3, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Buprenorphine And Naloxone
Generic name (nonproprietary): buprenorphine and naloxone
Active ingredients: Buprenorphine hydrochloride — 8 mg/1Naloxone hydrochloride — 2 mg/1
Dosage form: Tablet
Route: Sublingual
Labeler: Ascend Laboratories, LLCNDC labeler code 67877
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214930
Marketing start: Jul 3, 2026
Listing expires: Dec 31, 2027
DEA schedule: CIII
Other FDA classes: Opioid Antagonists (Mechanism)Partial Opioid Agonists (Mechanism)
Identifiers: Product ID 67877-606_f06091b6-2823-40db-bf86-e56a86db4532SPL ID f06091b6-2823-40db-bf86-e56a86db4532SPL set ID 2e807ed0-6df3-47b5-b7ee-b421c5bf0aa7RxCUI 351266, 351267UNII F850569PQR, 56W8MW3EN1
Pharmacologic class: Opioid Antagonist; Partial Opioid Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Sublingual products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N467877060630 followed by a unit qualifier and the quantity

Package 67877-0606-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 29, 2026.

Indications (excerpt from the label)

Buprenorphine and Naloxone Sublingual Tablets are indicated for the maintenance treatment of opioid dependence. Buprenorphine and Naloxone Sublingual Tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. Buprenorphine and Naloxone Sublingual Tablets contain buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist, and are indicated for the maintenance treatment of opioid dependence. ( 1 ) Buprenorphine and Naloxone Sublingual Tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 67877-606

What is NDC 67877-606?: 67877-606 is the product NDC for Buprenorphine And Naloxone, Buprenorphine hydrochloride 8 mg/1; Naloxone hydrochloride 2 mg/1 tablet, listed with the FDA by Ascend Laboratories, LLC. It has 3 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Buprenorphine And Naloxone.
What is the active ingredient?: Buprenorphine hydrochloride, Naloxone hydrochloride.
Who is the labeler?: Ascend Laboratories, LLC, NDC labeler code 67877. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Buprenorphine And Naloxone?: 50 other product NDCs are listed under this name. See all Buprenorphine And Naloxone NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Buprenorphine And Naloxone NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Buprenorphine And Naloxone	Buprenorphine hydrochloride 2 mg/1; Naloxone hydrochloride .5 mg/1	TabletSublingual	Ascend Laboratories, LLC	67877-607	67877-0607-3067877-0607-8467877-0607-90
Buprenorphine and Naloxone	Buprenorphine hydrochloride 2 mg/1; Naloxone hydrochloride .5 mg/1	Film, SolubleBuccal, Sublingual	Camber Pharmaceuticals, Inc.	31722-479	31722-0479-30
Buprenorphine and Naloxone	Buprenorphine hydrochloride 4 mg/1; Naloxone hydrochloride 1 mg/1	Film, SolubleBuccal, Sublingual	Camber Pharmaceuticals, Inc.	31722-480	31722-0480-30
Buprenorphine and Naloxone	Buprenorphine hydrochloride 8 mg/1; Naloxone hydrochloride 2 mg/1	Film, SolubleBuccal, Sublingual	Camber Pharmaceuticals, Inc.	31722-481	31722-0481-30
Buprenorphine and Naloxone	Buprenorphine hydrochloride 12 mg/1; Naloxone hydrochloride 3 mg/1	Film, SolubleBuccal, Sublingual	Camber Pharmaceuticals, Inc.	31722-482	31722-0482-30
Buprenorphine and Naloxone	Buprenorphine hydrochloride 8 mg/1; Naloxone hydrochloride dihydrate 2 mg/1	TabletSublingual	Unit Dose Solutions, Inc.	87441-001	87441-0001-01
Buprenorphine and Naloxone	Buprenorphine hydrochloride 2 mg/1; Naloxone hydrochloride dihydrate .5 mg/1	TabletSublingual	Camber Pharmaceuticals, Inc.	31722-850	31722-0850-30
Buprenorphine and Naloxone	Buprenorphine hydrochloride 8 mg/1; Naloxone hydrochloride dihydrate 2 mg/1	TabletSublingual	Camber Pharmaceuticals, Inc.	31722-851	31722-0851-30
Buprenorphine and Naloxone	Buprenorphine hydrochloride 2 mg/1; Naloxone hydrochloride .5 mg/1	FilmBuccal, Sublingual	Aveva Drug Delivery Systems Inc.	3215-6521	03215-6521-30
Buprenorphine and Naloxone	Buprenorphine hydrochloride 4 mg/1; Naloxone hydrochloride 1 mg/1	FilmBuccal, Sublingual	Aveva Drug Delivery Systems Inc.	3215-6522	03215-6522-30

All 51 Buprenorphine And Naloxone NDCs

Other NDCs under ANDA 214930

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214930
Product	Strength	Form · route	Labeler	Product NDC
Buprenorphine And Naloxone	Buprenorphine hydrochloride 2 mg/1; Naloxone hydrochloride .5 mg/1	TabletSublingual	Ascend Laboratories, LLC	67877-607